Building companies that grow fast and outperform expectations is nothing new for Peter Åberg. Three times he has been recognized as a Gazelle winner and once as a Supergazelle — the fastest-growing company among all limited companies. Now he has taken on the next challenge: together with Auxesis Pharma, bringing a groundbreaking pharmaceutical innovation to market.
Over his career, Peter Åberg has taken on a wide range of assignments — from founding and running technology companies to doubling and tripling sales in both U.S. pharmaceutical companies and recruitment firms. He has worked with leadership development within the UN, held demanding interim roles in municipalities and regions, and led mergers & acquisitions for international groups.
“Over the years I’ve learned what it takes for an organization to grow and succeed: clear leadership, strong team-building, sales focus, and cost control. The industry doesn’t matter — those elements are always decisive,” says Peter Åberg, CEO of Auxesis Pharma.
A solution the world has been looking for
With a background in the pharmaceutical industry, Peter saw the potential immediately when he came across Auxesis Pharma. The company is first in the world to stabilize acetylsalicylic acid in liquid form — an innovation that makes it possible to treat skin pain and irritation right away.
“Acetylsalicylic acid in tablet form has been used for more than a hundred years. But stabilizing it in liquid form is something no one has managed — until now. This is a product people around the world are searching for. Being part of building the market journey for an innovation like this is incredibly exciting,” says Peter.
For Peter, it is clear that no innovation succeeds without the right people behind it. He often returns to the importance of discipline, trust, and commitment within the team.
“The team is everything. To succeed, we must find the right people, create a culture with open dialogue where ideas can develop. At the same time, it takes clear discipline — you have to deliver, keep going, and endure. That’s what determines whether a startup survives or not.”
Medicines must create value for society
Another recurring theme in Peter’s career is sustainability. He has worked with Agenda 2030 issues and is a certification expert in ISO standards for environment and occupational health. For him, it is self-evident that Auxesis Pharma’s innovation must also contribute to societal benefit.
“I’m convinced that medicines must benefit society — not be driven by profit alone. Our products should be long-term, suitable even for children, and contribute to better health for more people. We carry sustainability thinking in everything we do — from product development to packaging and manufacturing,” says Peter.
Auxesis Pharma is now approaching the next stage: scaling up, attracting investments, and bringing the products to market — first in Sweden and the Nordics, then in Europe and the U.S. In parallel, new patents are being developed for more complex pain conditions such as cancer-related skin issues and burn injuries, as well as for veterinary medicine.
“We always have to start on our home market and prove that we can deliver sales. Then the plan is to expand internationally. A listing becomes a natural step to gain the strength to grow.”
For people — and for the future
Looking back on the recent period, there is one moment Peter is especially proud of: Auxesis Pharma has managed to get a formulation to work and meet the strict requirements of the Swedish Medical Products Agency.
“There is tremendous work behind achieving stability, solubility, and effect. No one else in the world has managed this before. Of course I’m proud — but I also know this is only the beginning.”